Digital Diabetes Prevention Program Cost-Effective for Preventing T2D
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 6, 2024 -- For individuals with prediabetes, a digital diabetes prevention program (d-DPP) is cost-effective compared with an in-person lifestyle intervention for preventing development of type 2 diabetes (T2D), according to a study published online July 26 in Diabetes, Obesity and Metabolism.
Sooyeol Park, from the Tulane University School of Public Health and Tropical Medicine in New Orleans, and colleagues examined the cost-effectiveness of a d-DPP versus a DPP for preventing T2D in individuals with prediabetes. A Markov cohort model was constructed, which simulated a 10-year period starting at 45 years of age.
The researchers found cost savings of $3,672 and $2,990 from a societal perspective and from a health care sector perspective, respectively, as well as a gain of 0.08 quality-adjusted life years resulting from the d-DPP intervention versus the DPP. A significant factor influencing the results was the dropout rate. The d-DPP intervention was preferred in 85.8 percent in the societal perspective and 85.2 percent in the health care sector perspective.
"Based on the current study's findings, d-DPPs can be an alternative to in-person DPPs. The cost savings of prevented cases of T2D with d-DPPs can improve the sustainability for patients with prediabetes," the authors write. "Our findings provide economic evidence that the d-DPP provides good value for money in preventing T2D in high-risk patients in the U.S. setting."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Generative AI Model for Draft Radiological Reporting Improves Documentation Efficiency
THURSDAY, June 12, 2025 -- Clinical use of artificial intelligence (AI)-generated draft radiograph reports is associated with improved radiologist documentation efficiency while...
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...
Mitochondrial Genetics Key to Metastatic Melanoma Immunotherapy Resistance
THURSDAY, June 12, 2025 -- For patients with metastatic melanoma, mitochondrial (MT) haplogroup T (HG-T) is associated with resistance to an anti-programmed cell death...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.